Cancer Supportive Care Drugs Market Updates : Estimated to Reach USD 25 Billion by 2032

According to a new report published by Allied Market Research, titled, "Cancer Supportive Care Drugs Market," The cancer supportive care drugs market was valued at $20.4 billion in 2022, and is estimated to reach $25 billion by 2032, growing at a CAGR of 2% from 2023 to 2032.

𝑹𝒆𝒒𝒖𝒆𝒔𝒕 𝑺𝒂𝒎𝒑𝒍𝒆 𝒐𝒇 𝒕𝒉𝒆 𝑹𝒆𝒑𝒐𝒓𝒕 - https://www.alliedmarketresearch.com/request-sample/A07133

Government initiatives aimed at enhancing cancer care significantly drive the growth of the cancer supportive care drugs market. For example, in May 2020, the federal government announced a $150 million investment over five years in the Canadian Partnership against Cancer, focusing on improving access to cancer care and supporting patients. Such initiatives underscore a commitment to advancing comprehensive cancer care and play a pivotal role in fostering innovation, research, and infrastructure development, shaping trends in the cancer supportive care drugs market.

Additionally, the increasing adoption of biosimilars presents a promising opportunity for cost-effective alternatives to biologic therapies, fostering competition and potentially reducing healthcare expenses. Regulatory approvals create a conducive environment for innovation and market expansion. For instance, in June 2021, Lupin Limited announced FDA acceptance of its Biologics License Application for a proposed biosimilar to Neulasta (pegfilgrastim), signaling opportunities for market growth. As pharmaceutical companies navigate regulatory pathways, an expanding portfolio of approved biosimilars enhances choices for clinicians and patients, contributing to overall growth and accessibility of cancer care.

However, advancements in targeted therapy for cancer and a shift towards more personalized treatments pose challenges to the cancer supportive care drugs market. Targeted therapies often result in fewer adverse effects, reducing the demand for traditional supportive care drugs addressing broader treatment-related side effects.

Segment-wise, the cancer supportive care drugs market analysis includes erythropoiesis-stimulating agents (ESA), granulocyte colony-stimulating factors (G-CSFs), antiemetics, bisphosphonates, opioids, NSAIDs, and others. The G-CSFs segment emerged as the largest in terms of revenue in 2022 and is anticipated to maintain its lead. G-CSFs play a crucial role in supporting cancer patients by stimulating white blood cell production, aiding in infection prevention during chemotherapy, thus driving their market share and revenue.

𝑻𝒉𝒆 𝑮-𝑪𝑺𝑭𝒔 (𝑮𝒓𝒂𝒏𝒖𝒍𝒐𝒄𝒚𝒕𝒆 𝒄𝒐𝒍𝒐𝒏𝒚-𝒔𝒕𝒊𝒎𝒖𝒍𝒂𝒕𝒊𝒏𝒈 𝒇𝒂𝒄𝒕𝒐𝒓𝒔) 𝒔𝒆𝒈𝒎𝒆𝒏𝒕 𝒕𝒐 𝒎𝒂𝒊𝒏𝒕𝒂𝒊𝒏 𝒊𝒕𝒔 𝒍𝒆𝒂𝒅 𝒑𝒐𝒔𝒊𝒕𝒊𝒐𝒏 𝒃𝒚 2030
By type, the G-CSFs (Granulocyte colony-stimulating factors) segment dominated the global cancer supportive care drugs market in 2020, holding more than two-fifths of the market share, and is projected to retain its leading position throughout the forecast period. This dominance is attributed to the growing prevalence of chemotherapy-induced neutropenia (CIN) and the rising demand for G-CSFs in its treatment. Conversely, the antiemetics segment is anticipated to experience the highest compound annual growth rate (CAGR) of 2.4% from 2021 to 2030.

𝑭𝒐𝒓 𝑷𝒖𝒓𝒄𝒉𝒂𝒔𝒆 𝑰𝒏𝒒𝒖𝒊𝒓𝒚 https://www.alliedmarketresearch.com/purchase-enquiry/A07133

Segmented by application, the market encompasses breast cancer, lung cancer, colorectal cancer, prostate cancer, liver cancer, stomach cancer, and others. The breast cancer segment emerged as the largest revenue contributor in the cancer supportive care drugs market in 2022 and is poised to maintain its dominance in the forecast period. This is attributed to the increasing prevalence of breast cancer and the adoption of various treatments often accompanied by side effects, driving the demand for supportive care drugs. The sustained necessity underscores the significant role of the breast cancer segment in driving market growth.

Conversely, the lung cancer segment is projected to witness the highest compound annual growth rate (CAGR) during the forecast period. The rising prevalence of lung cancer and the adoption of diverse treatments have led to a surge in cases, consequently increasing the demand for supportive care interventions. With growing awareness about the importance of comprehensive supportive care and expanding treatment options, there is a pressing need to address the unique challenges associated with lung cancer. This emphasis on supportive care is crucial for enhancing the quality of life for individuals affected by lung cancer, highlighting its pivotal role in managing the complexities of the disease and its treatments.

𝐓𝐡𝐞 𝐝𝐫𝐮𝐠 𝐬𝐭𝐨𝐫𝐞𝐬 𝐚𝐧𝐝 𝐫𝐞𝐭𝐚𝐢𝐥 𝐩𝐡𝐚𝐫𝐦𝐚𝐜𝐢𝐞𝐬 𝐬𝐞𝐠𝐦𝐞𝐧𝐭 𝐭𝐨 𝐦𝐚𝐢𝐧𝐭𝐚𝐢𝐧 𝐢𝐭𝐬 𝐥𝐞𝐚𝐝 𝐝𝐮𝐫𝐢𝐧𝐠 𝐭𝐡𝐞 𝐟𝐨𝐫𝐞𝐜𝐚𝐬𝐭 𝐩𝐞𝐫𝐢𝐨𝐝
In terms of end users, the drug stores and retail pharmacies segment held the largest market share in 2020, contributing to nearly half of the global cancer supportive care drugs market, and is expected to maintain its leadership in revenue generation throughout the forecast period. This dominance is credited to the growing number of drug stores and retail pharmacies offering both branded and generic cancer supportive care drugs, often accompanied by discounts and other benefits.

Conversely, the hospital pharmacies segment is anticipated to exhibit the highest compound annual growth rate (CAGR) of 2.3% from 2021 to 2030. This growth is driven by the convenience and flexibility offered by hospital pharmacies in obtaining drugs prescribed by medical professionals and doctors.

𝑵𝒐𝒓𝒕𝒉 𝑨𝒎𝒆𝒓𝒊𝒄𝒂 𝒕𝒐 𝒎𝒂𝒊𝒏𝒕𝒂𝒊𝒏 𝒊𝒕𝒔 𝒅𝒐𝒎𝒊𝒏𝒂𝒏𝒄𝒆 𝒃𝒚 2030
In terms of region, North America held the largest market share in 2020, contributing to approximately two-fifths of the global cancer supportive care drugs market, and is projected to maintain its dominant position by 2030. This can be attributed to factors such as the increasing prevalence of cancer, the strong presence of key players, extensive availability of drugs, early diagnosis practices, and favorable reimbursement policies within the region.

Conversely, the Asia-Pacific region is expected to experience the fastest compound annual growth rate (CAGR) of 2.3% from 2021 to 2030. This growth is driven by factors such as the rising healthcare expenditure and the adoption of strategic initiatives like mergers, acquisitions, and expansions by major market players in the Asia-Pacific region.

𝐋𝐞𝐚𝐝𝐢𝐧𝐠 𝐌𝐚𝐫𝐤𝐞𝐭 𝐏𝐥𝐚𝐲𝐞𝐫𝐬
Amgen Inc.
Baxter International Inc.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline Plc (GSK) (Tesaro)
Helsinn Healthcare
Heron Therapeutics
Johnson & Johnson (Janssen Global Services, LLC,)
Merck KGAA
Novartis International AG (Sandoz)
Teva Pharmaceuticals

𝑲𝒆𝒚 𝒇𝒊𝒏𝒅𝒊𝒏𝒈𝒔 𝒐𝒇 𝒕𝒉𝒆 𝒔𝒕𝒖𝒅𝒚
On the basis of type, the granulocyte colony-stimulating factors (G-CSFs) segment dominated the cancer supportive care drugs industry in terms of revenue in 2022. However, the antiemetics segment is anticipated to grow at the fastest CAGR during the forecast period.
On the basis of type, the breast cancer segment dominated the cancer supportive care drugs industry in terms of revenue in 2022. However, the lung cancer segment is anticipated to grow at the fastest CAGR during the forecast period.
On the basis of distribution channel, the drug stores and retail pharmacies segment dominated the market in terms of revenue in 2022. However, the online providers segment is anticipated to grow at the fastest CAGR during the forecast period.
Region wise, North America generated the largest revenue in 2022. However, Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

𝑲𝒏𝒐𝒘 𝑴𝒐𝒓𝒆-https://www.alliedmarketresearch.com/cancer-supportive-care-drugs-market-A07133

𝑶𝒕𝒉𝒆𝒓 𝑻𝒓𝒆𝒏𝒅𝒊𝒏𝒈 𝑹𝒆𝒑𝒐𝒓𝒕𝒔 𝒊𝒏 𝑳𝒊𝒇𝒆 𝑺𝒄𝒊𝒆𝒏𝒄𝒆 𝑫𝒐𝒎𝒂𝒊𝒏
𝑹𝒆𝒄𝒐𝒎𝒃𝒊𝒏𝒂𝒏𝒕 𝑽𝒂𝒄𝒄𝒊𝒏𝒆𝒔 𝑴𝒂𝒓𝒌𝒆𝒕 https://www.alliedmarketresearch.com/recombinant-vaccines-market-A17605

𝑺𝒉𝒂𝒓𝒑𝒔 𝑪𝒐𝒏𝒕𝒂𝒊𝒏𝒆𝒓𝒔 𝑴𝒂𝒓𝒌𝒆𝒕 https://www.alliedmarketresearch.com/sharps-containers-market-A17525

David Correa
5933 NE Win Sivers Drive
#205, Portland, OR 97220
United States
Toll Free: +1-800-792-5285
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
help@alliedmarketresearch.com
Web: https://www.alliedmarketresearch.com
Follow Us on: LinkedIn Twitter

Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.

We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.

This release was published on openPR.